Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,101 to 1,120 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Advanced glycation endproducts mediate chronic kidney injury with characteristic patterns in different stages. | Front Physiol | 2022 | 36160865 | PubTator, text mining | PubMed |
| A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers. | Mol Ther Oncolytics | 2022 | 36159778 | PubTator, text mining | PubMed |
| Diabetic kidney disease in pediatric patients: A current review. | World J Diabetes | 2022 | 36159227 | PubTator, text mining | PubMed |
| Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hope. | Front Oncol | 2022 | 36158670 | PubTator, text mining | PubMed |
| Identification of an amino acid metabolism-associated gene signature predicting the prognosis and immune therapy response of clear cell renal cell carcinoma. | Front Oncol | 2022 | 36158645 | PubTator, text mining | PubMed |
| Applying a clinical lens to animal models of CAR-T cell therapies. | Mol Ther Methods Clin Dev | 2022 | 36156878 | PubTator, text mining | PubMed |
| Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach. | Vaccines (Basel) | 2022 | 36146572 | PubTator, text mining | PubMed |
| Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. | Pharmaceutics | 2022 | 36145510 | PubTator, text mining | PubMed |
| Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies. | Int J Mol Sci | 2022 | 36142818 | PubTator, text mining | PubMed |
| Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. | Biomedicines | 2022 | 36140319 | PubTator, text mining | PubMed |
| Co-Stimulatory Receptor Signaling in CAR-T Cells. | Biomolecules | 2022 | 36139142 | PubTator, text mining | PubMed |
| The Landscape of Cell Death Processes with Associated Immunogenic and Fibrogenic Effects in Arrhythmogenic Cardiomyopathy. | J Cardiovasc Dev Dis | 2022 | 36135446 | PubTator, text mining | PubMed |
| Emerging Trends in Immunotherapy for Cancer. | Diseases | 2022 | 36135216 | PubTator, text mining | PubMed |
| Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma. | Front Immunol | 2022 | 36131934 | PubTator, text mining | PubMed |
| Progressive enhancement of kinetic proofreading in T cell antigen discrimination from receptor activation to DAG generation. | Elife | 2022 | 36125261 | PubTator, text mining | PubMed |
| CAR-T cell potency: from structural elements to vector backbone components. | Biomark Res | 2022 | 36123710 | PubTator, text mining | PubMed |
| Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors. | Cancer Immunol Res | 2022 | 36122411 | PubTator, text mining | PubMed |
| Comparing the Indian Autism Screening Questionnaire (IASQ) and the Indian Scale for Assessment of Autism (ISAA) with the Childhood Autism Rating Scale-Second Edition (CARS2) in Indian settings. | PLoS One | 2022 | 36121860 | PubTator, text mining | PubMed |
| The research progress of targeted therapy in acute myeloid leukemia based on bibliometric analysis. | Front Oncol | 2022 | 36119476 | PubTator, text mining | PubMed |
| Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. | Front Immunol | 2022 | 36119032 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=56